Crossmark

Real-life safety study of an accelerated cluster immunotherapy with a house dust mite native extract in patients with allergic rhinitis or rhinoconjunctivitis

Crossref DOI link: https://doi.org/10.1007/s40629-021-00168-4

Published Online: 2021-03-15

Published Print: 2021-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rodríguez Plata, Elena

Hernández Santana, Guacimara L.

Cubas Mesa, Estefanía

Coello Valeriano, Kevin

Matas Ros, María

Buendía Jiménez, Inmaculada
License Information

Text and Data Mining valid from 2021-03-15

Version of Record valid from 2021-03-15
More Information

Article History

Received: 8 January 2021

Accepted: 15 February 2021

First Online: 15 March 2021

Declarations

:

: M. Matas Ros is an employee of Probelte Pharma. I. Buendía Jiménez is an employee of Probelte Pharma. E. Rodríguez Plata, G.L. Hernández Santana, E. Cubas Mesa and K. Coello Valeriano declare that they have no competing interests.

: The study was approved by the ethic Committee from the <i>Complejo Hospitalario de Canarias</i> on September 26, 2019.

Document is current

Any future updates will be listed below